tbuckley/cabot-search huggingface dataset:
Abstract A12: Tumorigenic proteins upregulated in pediatric neuroblastoma MYCN-amplified tumorspheres confer radiotherapy resistance
Authors: Tamara Mary Abou-Antoun, Jad Helmi Abdallah, George Antoun Khazen, Zeina Nasr, Anthony Sandler
Journal: Cancer Research (2018)

Abstract Neuroblastoma is one of the most common extracranial central nervous system cancers of infancy with high mortality in children. We used SILAC proteomics to analyze the protein expression of the MYCN-amplified (IMR-32) and non-MYCN-amplified (SK-N-SH) human neuroblastoma stem-like tumorspheres after radiotherapy. More than 3,500 proteins were differentially expressed between the two cell types, and importantly many proteins were significantly upregulated in the IMR-32 compared to the SK-N-SH tumorspheres after radiotherapy, including the highly tumorigenic HSP90B (8-fold), prohibitin (4-fold), HMGA1 (15-fold), and FABP5 (3-fold). The top canonical pathways that the majority of the upregulated proteins in the neuroblastoma IMR-32 stem-like tumorspheres mapped to after radiotherapy included Actin Nucleation by ARP-WASP Complex; Signaling by Rho Family GTPases; Integrin Signaling; Cdc42 Signaling; and RhoGDI Signaling pathways. The associated network functions affiliated with these proteins were primarily cell death and survival, cell morphology, cellular function and maintenance; cell signaling, post-translational modification and protein synthesis; RNA post-transcriptional modification, molecular transport, RNA trafficking, and cancer. We sought to determine whether transcriptional knockdown of HMGA1 and FABP5 would radiosensitize these tumorspheres, as assessed by measuring the rate of cellular cytotoxicity, proliferation, and migration. IMR-32 neuroblastoma tumorspheres with transcriptional knockdown of HMGA1 and FABP5 exhibited lower rates of proliferation and migration, while cellular cytotoxicity was enhanced after 2Gy radiotherapy compared to nontransfected counterparts. Our finding suggests that HMGA1 and FABP5 may be contributing to the radiotherapy resistance of MYCN-amplified IMR-32 stem-like tumorspheres. Therapeutic resistance in the aggressive, MYCN-amplified high-risk group of pediatric neuroblastoma may be due to the upregulation of these highly tumorigenic proteins that are conferring protective mechanisms to this deadly childhood cancer. Citation Format: Tamara Mary Abou-Antoun, Jad Helmi Abdallah, George Antoun Khazen, Zeina Nasr, Anthony Sandler. Tumorigenic proteins upregulated in pediatric neuroblastoma MYCN-amplified tumorspheres confer radiotherapy resistance [abstract]. In: Proceedings of the AACR Special Conference: Pediatric Cancer Research: From Basic Science to the Clinic; 2017 Dec 3-6; Atlanta, Georgia. Philadelphia (PA): AACR; Cancer Res 2018;78(19 Suppl):Abstract nr A12.
Congenital X-Linked Myelodysplasia with Tetraploidy Is Associated with De Novo Germline C-Terminal Mutation of SEPT6, a Septin Filament Protein
Authors: Raffaele Renella, Katelyn Gagne, Ellen Beauchamp, Thorsten Schlaeger, Inga Hofmann, Akiko Shimamura, Jonathan Fogel, Suneet Agarwal, Benjamin L. Ebert, Kyriacos Markianos, Timothy A. Springer, Mark D. Fleming, David A. Williams
Journal: Blood (2018)
Understanding the Role of CSF3R and Runx1 Runt Homology Domain Missense Mutations in Leukemic Transformation of Hematopoietic Stem Cells
Authors: Malte U Ritter, Olga Klimenkova, Maksim Klimiankou, Amy E Schmidt, Carol Stocking, Lothar Kanz, Cornelia Zeidler, Daniel C. Link, Karl Welte, Julia Skokowa
Journal: Blood (2018)
Fast generation of IgE, IgG1 and IgG4 by PIPE cloning sharing the same variable region to the major birch pollen allergen Bet v 1
Authors: Verena K. Koehler, Judit F. Singer, Kristina M. Ilieva, Christina L. Pranger, Sophia N. Karagiannis, Erika Jensen-Jarolim
Journal: Journal of Allergy and Clinical Immunology (2019)
Splicing Factor Pathway Is Rarely Mutated in Myeloid Blast Phase of PV with Dysmyelopoiesis and Ring Sideroblast
Authors: Juliana Hidalgo Lopez, Rashmi Kanagal-Shamanna, Bryce Macek, Adrian Carballo-Zarate, Rafael Rojas Sáurez, Steven Reyes, Chong Zhao, Carlos E. Bueso-Ramos
Journal: Blood (2018)
The Need for an Intervention to Prevent Sports Injuries
Authors: Maguire Herriman, Maurice E. Schweitzer, Kevin G. Volpp
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Quality of Life Following Surgical Excision of Early-Stage Melanoma of the Head and Neck
Authors: John F. Thompson, Serigne Lo, Richard A Scolyer
Journal: JAMA Dermatology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Nintedanib versus placebo in patients receiving mFOLFOX6 for metastatic, chemorefractory colorectal cancer: TRICC-C trial—Final results from the randomized phase II trial of the AIO.
Authors: Thomas Jens Ettrich, Andreas Wolfgang Berger, Thomas Decker, Ralf Hofheinz, Volker Heinemann, Thomas Hoffmann, Holger Frithjof Hebart, Thomas Herrmann, Carla Verena Hannig, Petra Buechner-Steudel, Melanie Guethle, Hanna Bartholomaeus, Alica Beutel, Lukas Perkhofer, Thomas Seufferlein
Journal: Journal of Clinical Oncology (2019)

666 Background: Anti-VEGF agents plus chemotherapy improve PFS of patients with mCRC in the first- and second-line-setting. During this treatment tumour angiogenesis is driven by other factors but VEGF. Nintedanib, a triple angiokinase inhibitor of VEGFR-1-3, FGFR-1/-3 and PDGFR-α/-β, thereby additionally targets angiogenic escape mechanisms upon resistance to anti-VEGF treatment. The TRICC-C trial evaluates the combination of mFOLFOX6 plus Nintedanib. Final results of the randomized phase II trial are presented. Methods: Patients with mCRC having received one line of non-oxaliplatin containing palliative chemotherapy, with an ECOG-PS of 0/1 were randomized 1:1 in a double-blind design to receive: mFOLFOX6 plus Nintedanib (2 x 200 mg p.o./d, d1-d14) or placebo, respectively, repeated every 14 days. Primary endpoint was PFS. Secondary endpoints were ORR, OS and safety. Patients who received at least one dose of trial medication were included in the efficacy and safety analyses. Results: From 12/2012 to 5/2016 53 patients (scheduled n = 180) were randomized. The trial was terminated prematurely due to slow accrual. Compared to mFOLFOX6 plus placebo (F+P), the combination of mFOLFOX6 plus Nintedanib (F+N) improved mPFS (F+P: 4.6 vs. F+N: 8.1 mo.; HR 0.65; 95% CI 0.32-1.30; p = 0.2156), mOS (F+P: 9.9 vs. F+N: 17.1 mo.; HR 1.03, 95% CI 0.48-2.23; p = 0.9387) and DCR (F+P: 50 vs. F+N: 66,7%; p = 0.2709). ORR was comparable in both arms (F+N: 3.8 vs. F+P: 3.7%). Toxicity was low to moderate without major differences between both arms except G 3/4 neutropenia (F+N: 19%, F+P: 12%) and GI disorders (F+N: 23%, F+P: 15%). Conclusions: Final results suggest a PFS, OS and DCR benefit for mFOLFOX6 + Nintedanib in the second-line therapy of mCRC. Due to the premature termination of the trial there was no statistical significance demonstrable. Showing no clinically significant PFS-benefit in the first-line situation (mFOLFOX6 plus Nintedanib/Bevacizumab, Ann Oncol. 2015) or the last line as single agent, respectively (ESMO 2016) the TRICC-C results suggests that Nintedanib plus mFOLFOX6 could be an interesting therapeutic option for the second-line situation. Clinical trial information: NCT01362361.
A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study
Authors: Gordon Cook, Kara-Louise Royle, Charlotte Pawlyn, Anna Hockaday, Vallari Shah, Martin F Kaiser, Sarah R Brown, Walter M Gregory, J Anthony Child, Faith E Davies, Gareth J Morgan, David A Cairns, Graham H Jackson
Journal: The Lancet Haematology (2019)

BackgroundTolerability of treatments for multiple myeloma can depend on the characteristics of the patient being treated. We aimed to develop and validate a risk profile, using routinely collected data, that could predict overall survival in patients with multiple myeloma who were ineligible for stem-cell transplantation.MethodsWe used patient data from two randomised controlled trials done in patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation (the NCRI Myeloma XI study [NCRI-XI, n=1852] and the MRC Myeloma IX study [MRC-IX, n=520]), to develop the UK Myeloma Research Alliance Risk Profile (MRP) for overall survival. We used multivariable Cox regression with a least absolute shrinkage and selection operator penalty term. Multiple imputation by chained equations was used to account for missing data in the development and internal validation of the model. The MRP was internally validated in NCRI-XI and externally validated in MRC-IX. The D-statistic was estimated in the developed model and used to internally and externally validate the model according to prespecified criteria.FindingsThe MRP included WHO performance status, International Staging System, age, and C-reactive protein concentration as prognostic variables. The MRP was prognostic of overall survival and was successfully internally validated in NCRI-XI and externally validated in MRC-IX (D-statistic NCRI-XI: 0·840 [95% CI 0·718–0·963] and MRC-IX: 0·654 [0·497–0·811]). The MRP groups defining low-risk, medium-risk, and high-risk patients were associated with progression-free survival and early mortality. A decrease in the percentage of protocol dose delivered and quality of life at baseline were associated with increased risk. The MRP groups remained prognostic in patients exposed to different therapeutic combinations and in patients with genetic high-risk disease defined according to both the UK and International Myeloma Working Group definitions.InterpretationWe have developed and externally validated a risk profile for overall survival containing widely available clinical parameters. This risk profile could aid decision making in patients with multiple myeloma ineligible for stem-cell transplantation, but further external validation is required.FundingMedical Research Council, Novartis, Schering Health Care, Chugai, Pharmion, Celgene, Ortho Biotech, Cancer Research UK, Celgene, Merck Sharp & Dohme, and Amgen.
Abstract P265: Sex Differences in the Mediation of Relationship Between Depression and Nonadherence by Self-Efficacy
Authors: Erin Peacock, LaKeisha Williams, Paul Muntner, Donald Morisky, Marie Krousel-Wood
Journal: Circulation (2017)

Purpose: We tested for sex differences in how self-efficacy explains the relationship between incident depressive symptoms and incident low adherence using data from the Cohort Study of Medication Adherence among Older Adults (CoSMO). Methods: A telephone survey was administered to hypertensive older adults three times at yearly intervals. Depressive symptoms were defined as a score ≥16 on the Center for Epidemiologic Studies Depression Scale. Low adherence was defined as a score &lt;6 on the 8-item Morisky Medication Adherence Scale. Item scores on the 26-item Medication Adherence Self-Efficacy Scale were summed to create a self-efficacy score. Analysis was restricted to those without low adherence or depressive symptoms at baseline (n=1478). Mediation of the relationship between incident depressive symptoms and incident low adherence between baseline and first follow-up by self-efficacy at first follow-up was assessed using Baron &amp; Kenny’s procedures, modified to test for sex differences. Results: The sample was 58% female and 28% black, with a mean age of 75.2 years. The incidence of depressive symptoms and low adherence were 7.7% and 7.2%, respectively. The indirect effect (IE) – the portion of the effect of incident depressive symptoms on incident low adherence that is explained by self-efficacy - was significant for women (IE=0.029 95% CI 0.005, 0.068), such that 34.1% of the total effect of incident depressive symptoms on incident low adherence was explained by self-efficacy. The IE for women was significantly different from that for men (IE=-0.003 95% CI -0.019, 0.006). The direct effect of incident depressive symptoms on incident low adherence – the portion of the effect that is not explained by self-efficacy – was significantly different for women and men (direct effect (DE)=0.056 95% CI -0.082, 0.155 and DE=0.205 95% CI 0.060, 0.323, respectively). Conclusions: Self-efficacy explains some of the relationship between incident depressive symptoms and incident low adherence for women, but not for men.
Abstract 18760: Interactions Between Dietary Fiber and Gut Microbiota Modulate the Development of Atherosclerosis
Authors: Kazuyuki Kasahara, Robert L Kerby, Kymberleigh A Romano, Eugenio I Vivas, Margarete Mehrabian, Aldons J Lusis, Federico E Rey
Journal: Circulation (2016)

Diets rich in plant polysaccharides (i.e., fiber) confer protection against cardiovascular disease (CVD). Some of these benefits are derived from the interactions between carbohydrates that reach t...
Response to ‘‘To switch or not to switch’: the missing piece in the puzzle of biosimilar literature?’ by Scherlinger <i>et al</i>
Authors: Bente Glintborg, Anne Gitte Loft, Emina Omerovic, Oliver Hendricks, Asta Linauskas, Jakob Espesen, Kamilla Danebod, Dorte Vendelbo Jensen, Henrik Nordin, Emil Barner Dalgaard, Stavros Chrysidis, Salome Kristensen, Johnny Lillelund Raun, Hanne Lindegaard, Natalia Manilo, Susanne Højmark Jakobsen, Inger Marie Jensen Hansen, Dorte Dalsgaard Pedersen, Inge Juul Sørensen, Lis Smedegaard Andersen, Jolanta Grydehøj, Frank Mehnert, Niels Steen Krogh, Merete Lund Hetland
Journal: Annals of the Rheumatic Diseases (2019)

Thank you for the interest1 in our recent publication, in which we explored treatment outcomes following a Danish mandatory switch from originator to biosimilar etanercept (SB4, 50 mg) in routine care.2 We showed that of the 2061 patients who were receiving originator etanercept and thus were eligible for the switch, as many as four of five (79%) switched to the biosimilar, despite the continued availability of the originator drug (as 25 mg pen or 50 mg powder solution). Among the patients who switched, we observed high retention rates of the biosimilar. The 6-month …
Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses
Authors: Masaru Kanekiyo, M. Gordon Joyce, Rebecca A. Gillespie, John R. Gallagher, Sarah F. Andrews, Hadi M. Yassine, Adam K. Wheatley, Brian E. Fisher, David R. Ambrozak, Adrian Creanga, Kwanyee Leung, Eun Sung Yang, Seyhan Boyoglu-Barnum, Ivelin S. Georgiev, Yaroslav Tsybovsky, Madhu S. Prabhakaran, Hanne Andersen, Wing-Pui Kong, Ulrich Baxa, Kathryn L. Zephir, Julie E. Ledgerwood, Richard A. Koup, Peter D. Kwong, Audray K. Harris, Adrian B. McDermott, John R. Mascola, Barney S. Graham
Journal: Nature Immunology (2019)
Abstract P4-08-28: Clinical risk prediction models for breast cancer: A review of models developed between 2010 and 2018
Authors: S Siesling, T Hueting, B Tip, R Mentink, E Koffijberg
Journal: Cancer Research (2019)

Abstract Background: Clinical prediction models provide insight in the probability of a specified event happening based on the personal characteristics of the patient. Predicted probabilities support physicians in tailoring clinical decisions to the patients needs. Throughout the past decades, the amount of developed prediction models has grown, yet the application of these models in daily medical practice falls behind. It is currently uncertain how many prediction models exist to support decision making in breast cancer care and exactly which decisions may be supported using prediction models. This study aimed to identify all developed prediction models on breast cancer care and to assess the clinical applicability of the models in the target breast cancer population. Methods: A literature search was performed to identify developed risk prediction models published from January 2010 up to June 2018. Models predicting breast cancer related events were included. Identified models were assessed on the reported transparency and reproducibility and incorporated in the online platform for prediction models: Evidencio. Clinical applicability of the models was assessed using a digital implementation of the Dutch breast cancer guideline called Oncoguide. Models were assigned to location in the guideline where they may support clinical decisions. Results: A total of 91 studies describing the development of 142 prediction models were identified. Thorough assessment showed that 31 models were reported in full having the description of all the necessary parameters to reproduce the underlying statistical formula and were incorporated in Evidencio.com. For 95 models the formula could be derived through the presented nomogram, table, or online calculator. The remaining 16 models were lacking information to construct any method to predict the outcome of an individual patient and could therefore not be used in practice. Conclusion: A total of 142 prediction models were developed between January 2010 and June 2018. The overall quality of reporting was poor as 111 models were not described transparently. All identified models were assigned to the location in the guideline of which the model may support clinical decision making. Further assessment is necessary on the clinical impact and validity of the models in the Dutch population before implementing them in the guideline. Citation Format: Siesling S, Hueting T, Tip B, Mentink R, Koffijberg E. Clinical risk prediction models for breast cancer: A review of models developed between 2010 and 2018 [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-08-28.
Stage II and III rectal adenocarcinoma outcomes related to lymphovascular invasion.
Authors: Shalana BL O'Brien, Dorotea Mutabdzic, Elizabeth A. Handorf, Karthik Devarajan, Sanjay S. Reddy, Elin R. Sigurdson, Crystal S. Denlinger, Joshua E. Meyer, Jeffrey M. Farma
Journal: Journal of Clinical Oncology (2019)

698 Background: Lymphovascular invasion (LVI) has been shown to be associated with nodal involvement and higher rates of local recurrence in rectal cancer. In some studies, the presence of LVI has also been associated with worse overall survival; however, these have been mostly smaller, single institution studies or incomplete data sets. Our goal was to examine the effect of LVI on prognosis in a large and inclusive database. Methods: Outcomes of patients with clinical stage II and stage III rectal adenocarcinoma in the National Cancer Data Base (NCDB) from 2011 to 2015, in whom LVI data was available, were included. Exclusion criteria incorporated patients who did not receive neoadjuvant radiation and chemotherapy, neoadjuvant or adjuvant. Overall survival was compared in patients with and without LVI, controlling for age, sex, race, comorbidities, socioeconomic factors, and T and N stages using Kaplan-Meier survival curves and Cox proportional hazards regression analysis. Median overall survival and hazard ratios with 95% confidence intervals are reported where available. Results: The dataset included 9206 patients with stage II and 12640 patients with stage III rectal adenocarcinoma for which LVI data were available and who received the study’s previously defined standard of care. The proportion of patients with LVI was 11% in stage II and 16% in stage III rectal cancer. After adjusting for age, sex, race, T or N stage, and other clinical and demographic variables, LVI was associated with worse overall survival in stage II HR 1.87 (1.62-2.16, p &lt; 0.001) and in stage III HR 1.8 (1.61-2.02, p &lt; 0.001) rectal cancer. The median overall survival was not reached in stage II rectal cancer patients without LVI versus 5.73 years with LVI. In stage III rectal cancer, the median overall survival was 6.91 years without LVI versus 6.21 years with LVI. Conclusions: Lymphovascular invasion is an independent risk factor of mortality in stage II and III rectal cancer. Stage II rectal cancer patients without LVI have comparatively good survival of the groups studied, potentially identifying a group of patients that may benefit from de-escalated therapy. Further studies will be guided at identifying if benefits with chemotherapy are associated with LVI status.
Overview of the French Practice: Therapeutic Strategies in Patient's First Relapse or Refractory Non IgM AL Amyloidosis
Authors: Camille Villesuzanne, Stephanie Harel, Alexis Talbot, Bruno Royer, Naelle Lombion, Fabien Lebras, Mathilde Nouvier, Arnaud Jaccard, Bertrand Arnulf
Journal: Blood (2018)
Inclusion of neural effort in cost function can explain perceptual decision suboptimality
Authors: Yury P. Shimansky, Natalia Dounskaia
Journal: Behavioral and Brain Sciences (2018)

A more general form of optimality approach applied to the entire behavioral paradigm should be used instead of abandoning the optimality approach. Adding the cost of information processing to the optimality criterion and taking into account some other recently proposed aspects of decision optimization could substantially increase the explanatory power of an optimality approach to modeling perceptual decision making.
Better health and wellbeing for billion more people: integrating non-communicable diseases in primary care
Authors: Cherian Varghese, Baridalyne Nongkynrih, Igho Onakpoya, Marcy McCall, Shannon Barkley, Téa E Collins
Journal: BMJ (2019)

Cherian Varghese and colleagues describe a model to improve equitable access to good quality health services for non-communicable diseases within primary healthcare
Novel foods: Enzymatic and thermal food processing make edible insects non-allergenic
Authors: Desiree E.S. Larenas Linnemann, Pia Meinlschmidt, Benedict Purschke, Gerlinde Hofstetter, Fernanda A. Rodríguez Monroy, Lukas Einhorn, Nadine Mothes-Luksch, Henry Jaeger, Erika Jensen-Jarolim, Isabella Pali-Schoell
Journal: Journal of Allergy and Clinical Immunology (2019)